

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/151729 A1

(51) International Patent Classification:
A61K 38/16 (2006.01) *C07K 14/705* (2006.01)

VACIC, Cody; 230 Park Ave., Suite 2800, New York, New York 10169 (US).

(21) International Application Number:
PCT/US2025/011097

(74) Agent: **SMART, Danya et al.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(22) International Filing Date:
10 January 2025 (10.01.2025)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/619,705 10 January 2024 (10.01.2024) US
63/727,069 02 December 2024 (02.12.2024) US

(71) Applicant: **EVERCRISP BIOSCIENCES, INC.**
[US/US]; 230 Park Ave., Suite 2800, New York, New York 10169 (US).

(72) Inventors: **BERGUIG, Geoffrey Yehuda**; 230 Park Ave., Suite 2800, New York, New York 10169 (US). **KRI-**

(54) Title: MODIFIED CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: Aspects of the present disclosure relate to fusion polypeptides comprising a CRISPR-Cas effector polypeptide and a heterologous polypeptide (*e.g.*, a targeting moiety, an endosomal escape peptide, and/or a pH responsive polypeptide domain). In some aspects, the present disclosure provides compositions comprising a fusion polypeptide of the present disclosure and a guide nucleic acid. In some aspects, the present disclosure also provides fusion polynucleotides (*e.g.*, an oligonucleotide or a short interference RNA) and a heterologous polypeptide (*e.g.*, a targeting moiety, an endosomal escape peptide, and/or a pH responsive polypeptide domain). The present disclosure provides methods of modifying a target nucleic acid in a cell, such as a eukaryotic cell.

[Continued on next page]

WO 2025/151729 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*